AI-generated analysis. Always verify with the original filing.
ZyVersa Therapeutics, Inc. entered into a Securities Purchase Agreement on February 27, 2026, issuing $1 million in convertible promissory notes and Series A-4 Common Stock Purchase Warrants to accredited investors in a private placement, with net proceeds for working capital.
Event Type
Disclosure
Mandatory
Variant
8-K
Entry into a Material Definitive Agreement. On February 27, 2026, ZyVersa Therapeutics, Inc., a Delaware corporation (the “Company”), entered into a Securities
Financial Statements and Exhibits. Exhibit No. Description 4.1 Form of Series A-4 Common Stock Purchase Warrant. 10.1* Securities Purchase Agreement, dated Febr
Material Agreement
Debt / Financing